Cannabis
Commented by Carsten Mainitz on November 19th, 2021 | 13:13 CET
Sativa Wellness Group, Aurora Cannabis, TUI - Rising consumer spending on wellness and travel
According to Statista, the health and wellness market is worth around EUR 105 billion. More than USD 900 billion is spent annually worldwide on beauty and antiaging alone. Spending on travel is also increasing significantly after a sharp drop in the wake of the Corona pandemic. Reason enough to take a look at three stocks of industry representatives. Who is making the running?
Read
Commented by Fabian Lorenz on November 11th, 2021 | 13:02 CET
Bayer, TUI, Sativa Wellness: Figures move share prices
The reporting season is drawing to a close. Overall, most companies have been convincing, and the stock markets have been very friendly in recent weeks. Bayer published positive quarterly figures, raised its forecast for the full year and thus convinced the analysts from DZ Bank. Sativa Wellness benefits from the boom around cannabis and CBD. The still-new boom is growing strongly and is already in the black. At TUI, the operating figures play less of a role. The development of the Corona figures and, thus, possible travel restrictions in the coming winter are more critical. Read more about all three shares here.
Read
Commented by André Will-Laudien on October 28th, 2021 | 12:04 CEST
Canopy, Tilray, Sativa Wellness, Formycon - Finding the next cannabis rocket!
The big bull market in cannabis ran through 2018 and 2019, and then in 2020, the reality set in that only a fraction of states around the world will implement general licensing for hemp. The newly elected federal parliament has its first constituent session these days. Climate change and investments in digital infrastructure are two of the most important topics in the coalition negotiations to form a new federal government. One topic that is not quite so high on the list of priorities, but is already causing a lot of excitement in the run-up, is the possible legalization of cannabis. The Greens and FDP have been advocating legal, regulated trade for some time. Of course, nothing has been decided yet, but the outgoing federal government's drug commissioner, Daniela Ludwig of the CSU, already warns of the consequences. We take a look at important industry representatives.
Read
Commented by Stefan Feulner on October 26th, 2021 | 11:37 CEST
Tilray, Ayurcann, Aurora Cannabis, Canopy Growth - Sow first, then reap
After the hype around cannabis companies like Aurora Cannabis, Tilray and Canopy Growth in 2018, consolidation followed, and it continues. But the industry is moving mightily. Smaller companies disappeared from the price list, while big players expanded their market power through mergers and acquisitions for the next few years. The cannabis industry is predicted to grow tremendously in the future. The fantasy is fueled by government legalization plans in several states, including Germany.
Read
Commented by Stefan Feulner on March 4th, 2021 | 09:16 CET
NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!
The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!
Read
Commented by André Will-Laudien on December 7th, 2020 | 10:01 CET
EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!
The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.
Read
Commented by Mario Hose on July 15th, 2020 | 12:23 CEST
BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential
In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.
Read
Commented by Mario Hose on May 19th, 2020 | 15:02 CEST
Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!
The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.
Read
Commented by Mario Hose on March 23rd, 2020 | 15:00 CET
Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona
The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.
Read
Commented by Mario Hose on February 25th, 2020 | 13:38 CET
Aurora Cannabis, Canopy Growth, EXMceuticals - who will be the best turnaround story?
Cannabis shares are not in demand at the moment. About a year ago the growth potential and possibilities of the rediscovered historical medicinal plant seemed to be endless. Today it is different, there is a hangover mood. The hype back then led to a buyer's market. Investors underbid each other with purchase orders and shareholders surrendered their shares in a nervous mood in order to set off for new shores. This or something similar may be the current situation in the environment of numerous cannabis companies. But experienced investors also know that consolidation phases are the foundation for success stories.
Read